Envestnet Asset Management’s ProKidney PROK Stock Holding History

Envestnet Asset Management’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,340	Closed	-$61.1K	–	4139
2023 Q3	$61.1K	Buy	+13,340	New	+$128K	﹤0.01%	3925

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Brown University Providence, Rhode Island $102M AUM 26.79% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Envestnet Asset Management's PROK Position: Q4 2023 in Review

Envestnet Asset Management sold out of ProKidney (PROK) in Q4 2023, closing a stake of 13,340 shares — an estimated $61.1K sold.

Envestnet Asset Management first reported a position in PROK in Q3 2023 and held it in 1 quarter. The position peaked at $61.1K in Q3 2023. 61 funds tracked by Wall St. Rank hold PROK as of Q4 2023.

Envestnet Asset Management reported no remaining ProKidney position as of Q4 2023 after selling out during the quarter.
Envestnet Asset Management sold 13,340 ProKidney shares in Q4 2023, an estimated $61.1K.
Envestnet Asset Management first reported a position in ProKidney in Q3 2023 and held it in 1 quarter.
Envestnet Asset Management's ProKidney position peaked at $61.1K in Q3 2023.
61 funds tracked by Wall St. Rank held ProKidney as of Q4 2023.

Based on Envestnet Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.